{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:42:54Z","timestamp":1789677774305,"version":"4.0.1"},"reference-count":165,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Health Research Council of New Zealand","award":["20\/317"],"award-info":[{"award-number":["20\/317"]}]},{"name":"Health Research Council of New Zealand","award":["22\/028"],"award-info":[{"award-number":["22\/028"]}]},{"name":"Health Research Council of New Zealand","award":["2001 FFE"],"award-info":[{"award-number":["2001 FFE"]}]},{"name":"Health Research Council of New Zealand","award":["1121013"],"award-info":[{"award-number":["1121013"]}]},{"name":"New Zealand Optometric Vision Research Foundation","award":["20\/317"],"award-info":[{"award-number":["20\/317"]}]},{"name":"New Zealand Optometric Vision Research Foundation","award":["22\/028"],"award-info":[{"award-number":["22\/028"]}]},{"name":"New Zealand Optometric Vision Research Foundation","award":["2001 FFE"],"award-info":[{"award-number":["2001 FFE"]}]},{"name":"New Zealand Optometric Vision Research Foundation","award":["1121013"],"award-info":[{"award-number":["1121013"]}]},{"name":"Health Research Council of New Zealand","award":["20\/317"],"award-info":[{"award-number":["20\/317"]}]},{"name":"Health Research Council of New Zealand","award":["22\/028"],"award-info":[{"award-number":["22\/028"]}]},{"name":"Health Research Council of New Zealand","award":["2001 FFE"],"award-info":[{"award-number":["2001 FFE"]}]},{"name":"Health Research Council of New Zealand","award":["1121013"],"award-info":[{"award-number":["1121013"]}]},{"name":"Buchanan Charitable Foundation","award":["20\/317"],"award-info":[{"award-number":["20\/317"]}]},{"name":"Buchanan Charitable Foundation","award":["22\/028"],"award-info":[{"award-number":["22\/028"]}]},{"name":"Buchanan Charitable Foundation","award":["2001 FFE"],"award-info":[{"award-number":["2001 FFE"]}]},{"name":"Buchanan Charitable Foundation","award":["1121013"],"award-info":[{"award-number":["1121013"]}]},{"name":"Neurological Foundation of New Zealand First Fellowship","award":["20\/317"],"award-info":[{"award-number":["20\/317"]}]},{"name":"Neurological Foundation of New Zealand First Fellowship","award":["22\/028"],"award-info":[{"award-number":["22\/028"]}]},{"name":"Neurological Foundation of New Zealand First Fellowship","award":["2001 FFE"],"award-info":[{"award-number":["2001 FFE"]}]},{"name":"Neurological Foundation of New Zealand First Fellowship","award":["1121013"],"award-info":[{"award-number":["1121013"]}]},{"name":"Auckland Medical Research Foundation Project Grant","award":["20\/317"],"award-info":[{"award-number":["20\/317"]}]},{"name":"Auckland Medical Research Foundation Project Grant","award":["22\/028"],"award-info":[{"award-number":["22\/028"]}]},{"name":"Auckland Medical Research Foundation Project Grant","award":["2001 FFE"],"award-info":[{"award-number":["2001 FFE"]}]},{"name":"Auckland Medical Research Foundation Project Grant","award":["1121013"],"award-info":[{"award-number":["1121013"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Dry eye disease (DED) is a multifactorial ocular surface disorder arising from numerous interrelated underlying pathologies that trigger a self-perpetuating cycle of instability, hyperosmolarity, and ocular surface damage. Associated ocular discomfort and visual disturbance contribute negatively to quality of life. Ocular surface inflammation has been increasingly recognised as playing a key role in the pathophysiology of chronic DED. Current readily available anti-inflammatory agents successfully relieve symptoms, but often without addressing the underlying pathophysiological mechanism. The NOD-like receptor protein-3 (NLRP3) inflammasome pathway has recently been implicated as a key driver of ocular surface inflammation, as reported in pre-clinical and clinical studies of DED. This review discusses the intimate relationship between DED and inflammation, highlights the involvement of the inflammasome in the development of DED, describes existing anti-inflammatory therapies and their limitations, and evaluates the potential of the inflammasome in the context of the existing anti-inflammatory therapeutic landscape as a therapeutic target for effective treatment of the disease.<\/jats:p>","DOI":"10.3390\/ijms241310866","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:43:30Z","timestamp":1688085810000},"page":"10866","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["NLRP3 Inflammasome as a Potential Therapeutic Target in Dry Eye Disease"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0771-3869","authenticated-orcid":false,"given":"Dian","family":"Zhuang","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, New Zealand National Eye Centre, Faculty of Medical and Health Sciences, The University of Auckland, Auckland 1142, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3854-2991","authenticated-orcid":false,"given":"Stuti L.","family":"Misra","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, New Zealand National Eye Centre, Faculty of Medical and Health Sciences, The University of Auckland, Auckland 1142, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4519-6727","authenticated-orcid":false,"given":"Odunayo O.","family":"Mugisho","sequence":"additional","affiliation":[{"name":"Buchanan Ocular Therapeutics Unit, Department of Ophthalmology, New Zealand National Eye Centre, Faculty of Medical and Health Sciences, The University of Auckland, Auckland 1142, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5997-5994","authenticated-orcid":false,"given":"Ilva D.","family":"Rupenthal","sequence":"additional","affiliation":[{"name":"Buchanan Ocular Therapeutics Unit, Department of Ophthalmology, New Zealand National Eye Centre, Faculty of Medical and Health Sciences, The University of Auckland, Auckland 1142, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8297-5319","authenticated-orcid":false,"given":"Jennifer P.","family":"Craig","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, New Zealand National Eye Centre, Faculty of Medical and Health Sciences, The University of Auckland, Auckland 1142, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"TFOS DEWS II Definition and Classification Report","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul. Surf."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jtos.2017.05.011","article-title":"TFOS DEWS II Pathophysiology Report","volume":"15","author":"Bron","year":"2017","journal-title":"Ocul. Surf."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1167\/iovs.10-6997g","article-title":"The International Workshop on Meibomian Gland Dysfunction: Report of the Subcommittee on Management and Treatment of Meibomian Gland Dysfunction Gerd","volume":"52","author":"Geerling","year":"2011","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1167\/iovs.09-4445","article-title":"Screening for Meibomian Gland Disease: Its Relation to Dry Eye Subtypes and Symptoms in a Tertiary Referral Clinic in Singapore","volume":"51","author":"Tong","year":"2010","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/opo.12349","article-title":"A Comparison of the Self-Reported Dry Eye Practices of New Zealand Optometrists and Ophthalmologists","volume":"37","author":"Xue","year":"2017","journal-title":"Ophthalmic Physiol. Opt."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"DES192","DOI":"10.1167\/iovs.17-23651","article-title":"Inflammatory Response in Dry Eye","volume":"59","author":"Yamaguchi","year":"2018","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/ICL.0000000000000643","article-title":"A New Perspective on Dry Eye Classification: Proposal by the Asia Dry Eye Society","volume":"46","author":"Tsubota","year":"2020","journal-title":"Eye Contact Lens"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1136\/bjophthalmol-2015-307415","article-title":"Revisiting the Vicious Circle of Dry Eye Disease: A Focus on the Pathophysiology of Meibomian Gland Dysfunction","volume":"100","author":"Baudouin","year":"2016","journal-title":"Br. J. Ophthalmol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1001\/archophthalmol.2011.364","article-title":"Dry Eye Disease An Immune-Mediated Ocular Surface Disorder","volume":"130","author":"Stevenson","year":"2012","journal-title":"Arch. Ophthalmol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.preteyeres.2012.02.003","article-title":"Ocular Surface Immunity: Homeostatic Mechanisms and Their Disruption in Dry Eye Disease","volume":"31","author":"Barabino","year":"2012","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_11","first-page":"2921","article-title":"Cyclosporine A Micellar Delivery System for Dry Eyes","volume":"11","author":"Kang","year":"2016","journal-title":"Int. J. Nanomed."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.exer.2014.05.001","article-title":"Reactive Oxygen Species Activated NLRP3 Inflammasomes Prime Environment-Induced Murine Dry Eye","volume":"125","author":"Zheng","year":"2014","journal-title":"Exp. Eye Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.exer.2015.02.013","article-title":"Reactive Oxygen Species Activated NLRP3 Inflammasomes Initiate Inflammation in Hyperosmolarity Stressed Human Corneal Epithelial Cells and Environment-Induced Dry Eye Patients","volume":"134","author":"Zheng","year":"2015","journal-title":"Exp. Eye Res."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Niu, L., Zhang, S., Wu, J., Chen, L., and Wang, Y. (2015). Upregulation of NLRP3 Inflammasome in the Tears and Ocular Surface of Dry Eye Patients. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0126277"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jtos.2013.07.003","article-title":"Role of Hyperosmolarity in the Pathogenesis and Management of Dry Eye Disease: Proceedings of the Ocean Group Meeting","volume":"11","author":"Baudouin","year":"2013","journal-title":"Ocul. Surf."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S1542-0124(12)70148-9","article-title":"Inflammation in Dry Eye","volume":"2","author":"Stern","year":"2004","journal-title":"Ocul. Surf."},{"key":"ref_17","first-page":"210","article-title":"Determination of Inmune Response and Inflammation Mediators in Tears: Changes in Dry Eye and Glaucoma as Compared to Healthy Controls","volume":"92","year":"2017","journal-title":"Arch. Soc. Esp. Oftalmol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"(2007). The Definition and Classification of Dry Eye Disease: Report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop. Ocul. Surf., 5, 75\u201392.","DOI":"10.1016\/S1542-0124(12)70081-2"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/ICL.0000000000000042","article-title":"The Core Mechanism of Dry Eye Disease Is Inflammation","volume":"40","author":"Wei","year":"2014","journal-title":"Eye Contact Lens"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1136\/bjo.57.11.852","article-title":"Histology of the Lacrimal Gland in Keratoconjunctivitis Sicca","volume":"57","author":"Williamson","year":"1973","journal-title":"Br. J. Ophthalmol."},{"key":"ref_21","first-page":"2609","article-title":"Conjunctival T-Cell Subpopulations in Sjogren\u2019s and Non-Sjogren\u2019s Patients with Dry Eye","volume":"43","author":"Stern","year":"2002","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3109\/09273941003721926","article-title":"Dry Eye Disease as an Inflammatory Disorder","volume":"18","author":"Calonge","year":"2010","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.exer.2005.08.019","article-title":"JNK and ERK MAP Kinases Mediate Induction of IL-1\u03b2, TNF-\u03b1 and IL-8 Following Hyperosmolar Stress in Human Limbal Epithelial Cells","volume":"82","author":"Li","year":"2006","journal-title":"Exp. Eye Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1167\/iovs.08-2417","article-title":"Characterization of Effector T Cells in Dry Eye Disease","volume":"50","author":"Annan","year":"2009","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/mi.2009.5","article-title":"IL-17 Disrupts Corneal Barrier Following Desiccating Stress","volume":"2","author":"Chotikavanich","year":"2009","journal-title":"Mucosal Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/mi.2010.26","article-title":"Autoimmunity at the Ocular Surface: Pathogenesis and Regulation","volume":"3","author":"Stern","year":"2010","journal-title":"Mucosal Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Tsubota, K., Pflugfelder, S.C., Liu, Z., Baudouin, C., Myung Kim, H., Messmer, E.M., Kruse, F., Liang, L., Tatiana Carreno-Galeano, J., and Rolando, M. (2020). Defining Dry Eye from a Clinical Perspective. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21239271"},{"key":"ref_28","first-page":"1","article-title":"The IL-1 Family and Inflammatory Diseases","volume":"20","author":"Dinarello","year":"2002","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1749-6632.1989.tb24028.x","article-title":"Regulation of Expression of Interleukin-6: Molecular and Clinical Studies","volume":"557","author":"Ray","year":"1989","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2567.2009.03240.x","article-title":"Interleukin-17 and Its Target Genes: Mechanisms of Interleukin-17 Function in Disease","volume":"129","author":"Onishi","year":"2010","journal-title":"Immunology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.2217\/imt.12.137","article-title":"Immunotherapeutic Applications of IL-18","volume":"4","author":"Tsutsui","year":"2012","journal-title":"Immunotherapy"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/OPX.0000000000000133","article-title":"Quantification of Conjunctival TNF-\u03b1 in Aqueous-Deficient Dry Eye","volume":"91","author":"Caffery","year":"2014","journal-title":"Optom. Vis. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6279","DOI":"10.1167\/iovs.10-7081","article-title":"Interferon-\u03b3 Exacerbates Dry Eye-Induced Apoptosis in Conjunctiva through Dual Apoptotic Pathways","volume":"52","author":"Zhang","year":"2011","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1002\/eji.201344081","article-title":"Donor and Host B Cell-Derived IL-10 Contributes to Suppression of Graft-versus-Host Disease","volume":"44","author":"Weber","year":"2014","journal-title":"Eur. J. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1189\/jlb.1110611","article-title":"Interferon-Gamma-Secreting NK Cells Promote Induction of Dry Eye Disease","volume":"89","author":"Chen","year":"2011","journal-title":"J. Leukoc. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/ICO.0b013e318033a729","article-title":"Strain-Related Cytokine Profiles on the Murine Ocular Surface in Response to Desiccating Stress","volume":"26","author":"Corrales","year":"2007","journal-title":"Cornea"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/rheumatology\/kep357","article-title":"Age-Related T-Cell Cytokine Profile Parallels Corneal Disease Severity in Sj\u00f6gren\u2019s Syndrome-like Keratoconjunctivitis Sicca in CD25KO Mice","volume":"49","author":"Hwang","year":"2010","journal-title":"Rheumatology"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"De Paiva, C.S., Volpe, E.A., Gandhi, N.B., Zhang, X., Zheng, X., Pitcher, J.D., Farley, W.J., Stern, M.E., Niederkorn, J.Y., and Li, D.Q. (2011). Disruption of TGF-\u03b2 Signaling Improves Ocular Surface Epithelial Disease in Experimental Autoimmune Keratoconjunctivitis Sicca. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0029017"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1167\/iovs.03-1145","article-title":"Experimental Dry Eye Stimulates Production of Inflammatory Cytokines and MMP-9 and Activates MAPK Signaling Pathways on the Ocular Surface","volume":"45","author":"Luo","year":"2004","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/ICO.0b013e31816bf46c","article-title":"Interleukin-1 Receptor-1-Deficient Mice Show Attenuated Production of Ocular Surface Inflammatory Cytokines in Experimental Dry Eye","volume":"27","author":"Narayanan","year":"2008","journal-title":"Cornea"},{"key":"ref_41","first-page":"862","article-title":"Tear Cytokine and Chemokine Analysis and Clinical Correlations in Evaporative-Type Dry Eye Disease","volume":"16","author":"Castellanos","year":"2010","journal-title":"Mol. Vis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ajo.2008.08.032","article-title":"Tear Cytokine Profiles in Dysfunctional Tear Syndrome","volume":"147","author":"Lam","year":"2009","journal-title":"Am. J. Ophthalmol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1097\/ICO.0b013e3181a16578","article-title":"Analysis of Inflammatory Cytokines in the Tears of Dry Eye Patients","volume":"28","author":"Massingale","year":"2009","journal-title":"Cornea"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1076\/ceyr.19.3.201.5309","article-title":"Altered Cytokine Balance in the Tear Fluid and Conjunctiva of Patients with Sj\u00f6gren\u2019s Syndrome Keratoconjunctivitis Sicca","volume":"19","author":"Pflugfelder","year":"2009","journal-title":"Curr. Eye Res."},{"key":"ref_45","first-page":"2283","article-title":"Pro- and Anti-Inflammatory Forms of Interleukin-1 in the Tear Fluid and Conjunctiva of Patients with Dry-Eye Disease","volume":"42","author":"Solomon","year":"2001","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1016\/S0161-6420(98)91236-2","article-title":"Elevated Tear Interleukin-6 Levels in Patients with Sjogren Syndrome","volume":"105","author":"Tishler","year":"1998","journal-title":"Ophthalmology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1167\/iovs.08-2476","article-title":"Production and Activity of Matrix Metalloproteinase-9 on the Ocular Surface Increase in Dysfunctional Tear Syndrome","volume":"50","author":"Chotikavanich","year":"2009","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1096\/fasebj.5.8.1850705","article-title":"Matrix Metalloproteinases and Their Inhibitors in Connective Tissue Remodeling","volume":"5","author":"Woessner","year":"1991","journal-title":"FASEB J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1167\/iovs.04-0299","article-title":"Stimulation of Matrix Metalloproteinases by Hyperosmolarity via a JNK Pathway in Human Corneal Epithelial Cells","volume":"45","author":"Li","year":"2004","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0002-9440(10)62232-8","article-title":"Matrix Metalloproteinase-9 Knockout Confers Resistance to Corneal Epithelial Barrier Disruption in Experimental Dry Eye","volume":"166","author":"Pflugfelder","year":"2005","journal-title":"Am. J. Pathol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1159\/000150445","article-title":"Inflammatory Markers in the Tears of Patients with Ocular Surface Disease","volume":"40","author":"Acera","year":"2008","journal-title":"Ophthalmic Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.exer.2018.12.004","article-title":"Corneal Regeneration by Conditioned Medium of Human Uterine Cervical Stem Cells Is Mediated by TIMP-1 and TIMP-2","volume":"180","author":"Seoane","year":"2019","journal-title":"Exp. Eye Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1053\/beha.2000.0097","article-title":"The HLA System in Blood Transfusion","volume":"13","author":"Navarrete","year":"2000","journal-title":"Best. Pract. Res. Clin. Haematol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.exer.2013.03.018","article-title":"HLA-DR Expression as a Biomarker of Inflammation for Multicenter Clinical Trials of Ocular Surface Disease","volume":"111","author":"Epstein","year":"2013","journal-title":"Exp. Eye Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.3389\/fimmu.2018.02271","article-title":"Conjunctival Inflammatory Gene Expression Profiling in Dry Eye Disease: Correlations with HLA-DRA and HLA-DRB1","volume":"9","author":"Kessal","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_56","first-page":"28","article-title":"Regulation of Human Leukocyte Antigen Expression in Human Conjunctival Epithelium","volume":"40","author":"Tsubota","year":"1999","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_57","first-page":"1356","article-title":"Flow Cytometric Analysis of Inflammatory Markers in Conjunctival Epithelial Cells of Patients with Dry Eyes","volume":"41","author":"Brignole","year":"2000","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/S0161-6420(00)00347-X","article-title":"Flow Cytometric Analysis of Conjunctival Epithelium in Ocular Rosacea and Keratoconjunctivitis Sicca","volume":"107","author":"Pisella","year":"2000","journal-title":"Ophthalmology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"5488","DOI":"10.1167\/iovs.11-7215","article-title":"Hyperosmolar Stress Upregulates HLA-DR Expression in Human Conjunctival Epithelium in Dry Eye Patients and In Vitro Models","volume":"52","author":"Versura","year":"2011","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1167\/iovs.15-16555","article-title":"Correlation between the Inflammatory Marker HLA-DR and Signs and Symptoms in Moderate to Severe Dry Eye Disease","volume":"58","author":"Riancho","year":"2017","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0167-5699(94)90002-7","article-title":"The Role of Cell Adhesion Molecules in Immunopathology","volume":"15","author":"Gorski","year":"1994","journal-title":"Immunol. Today"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1089\/jop.2016.0105","article-title":"LFA-1\/ICAM-1 Interaction as a Therapeutic Target in Dry Eye Disease","volume":"33","author":"Pflugfelder","year":"2017","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","article-title":"The Inflammasome: A Molecular Platform Triggering Activation of Inflammatory Caspases and Processing of ProIL-\u03b2","volume":"10","author":"Martinon","year":"2002","journal-title":"Mol. Cell"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fphar.2015.00262","article-title":"NLRP3 Inflammasome and Its Inhibitors: A Review","volume":"6","author":"Shao","year":"2015","journal-title":"Front. Pharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.cell.2010.01.040","article-title":"The Inflammasomes","volume":"140","author":"Schroder","year":"2010","journal-title":"Cell"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2147\/JIR.S141220","article-title":"Spotlight on the NLRP3 Inflammasome Pathway","volume":"11","author":"Groslambert","year":"2018","journal-title":"J. Inflamm. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1097\/OPX.0000000000001802","article-title":"Impact of Low Humidity on Damage-Associated Molecular Patterns at the Ocular Surface during Dry Eye Disease","volume":"98","author":"Alven","year":"2021","journal-title":"Optom. Vis. Sci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.smim.2009.05.002","article-title":"The NLRP3 Inflammasome: A Sensor of Immune Danger Signals","volume":"21","author":"Cassel","year":"2009","journal-title":"Semin. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"787","DOI":"10.4049\/jimmunol.0901363","article-title":"Cutting Edge: NF-\u039aB Activating Pattern Recognition and Cytokine Receptors License NLRP3 Inflammasome Activation by Regulating NLRP3 Expression","volume":"183","author":"Bauernfeind","year":"2009","journal-title":"J. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.1998.tb08307.x","article-title":"Interleukin-1\u03b2, Interleukin-18, and the Interleukin-1\u03b2 Converting Enzyme","volume":"856","author":"Dinarello","year":"1998","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/cea.12206","article-title":"The NLRP3 Inflammasome: Role in Airway Inflammation","volume":"44","author":"Im","year":"2014","journal-title":"Clin. Exp. Allergy"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/cr.2015.139","article-title":"Gasdermin D Is an Executor of Pyroptosis and Required for Interleukin-1\u03b2 Secretion","volume":"25","author":"He","year":"2015","journal-title":"Cell Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nature18629","article-title":"Inflammasome-Activated Gasdermin D Causes Pyroptosis by Forming Membrane Pores","volume":"535","author":"Liu","year":"2016","journal-title":"Nature"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/nature15514","article-title":"Cleavage of GSDMD by Inflammatory Caspases Determines Pyroptotic Cell Death","volume":"526","author":"Shi","year":"2015","journal-title":"Nature"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2567.2010.03283.x","article-title":"Regulation of Inflammasome Activity","volume":"130","author":"Guarda","year":"2010","journal-title":"Immunology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2337\/db12-0420","article-title":"Upregulated NLRP3 Inflammasome Activation in Patients with Type 2 Diabetes","volume":"62","author":"Lee","year":"2013","journal-title":"Diabetes"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nm.2717","article-title":"NLRP3 Has a Protective Role in Age-Related Macular Degeneration through the Induction of IL-18 by Drusen Components","volume":"18","author":"Doyle","year":"2012","journal-title":"Nat. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1167\/iovs.12-10849","article-title":"Inflammatory Mediators Induced by Amyloid-Beta in the Retina and RPE In Vivo: Implications for Inflammasome Activation in Age-Related Macular Degeneration","volume":"54","author":"Liu","year":"2013","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Mugisho, O.O., Green, C.R., Zhang, J., Binz, N., Acosta, M.L., Rakoczy, E., and Rupenthal, I.D. (2017). Immunohistochemical Characterization of Connexin43 Expression in a Mouse Model of Diabetic Retinopathy and in Human Donor Retinas. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18122567"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00109-018-1727-5","article-title":"Connexin43 Hemichannel Block Protects against the Development of Diabetic Retinopathy Signs in a Mouse Model of the Disease","volume":"97","author":"Mugisho","year":"2019","journal-title":"J. Mol. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1167\/iovs.12-11047","article-title":"IL-1\u03b2 Triggered by Peptidoglycan and Lipopolysaccharide through TLR2\/4 and ROS-NLRP3 Inflammasome- Dependent Pathways Is Involved in Ocular Beh\u00e7et\u2019s Disease","volume":"54","author":"Liang","year":"2013","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1016\/j.drudis.2021.06.017","article-title":"Blocking the Inflammasome: A Novel Approach to Treat Uveitis","volume":"26","author":"Shome","year":"2021","journal-title":"Drug. Discov. Today"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"108618","DOI":"10.1016\/j.exer.2021.108618","article-title":"The Role of the Inflammasomes in the Pathogenesis of Uveitis","volume":"208","author":"Xu","year":"2021","journal-title":"Exp. Eye Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fnmol.2019.00036","article-title":"Inflammasome Activation Induces Pyroptosis in the Retina Exposed to Ocular Hypertension Injury","volume":"12","author":"Pronin","year":"2019","journal-title":"Front. Mol. Neurosci."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jaut.2017.02.006","article-title":"Mitochondrial DNA Oxidation Induces Imbalanced Activity of NLRP3\/NLRP6 Inflammasomes by Activation of Caspase-8 and BRCC36 in Dry Eye","volume":"80","author":"Chi","year":"2017","journal-title":"J. Autoimmun."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1007\/BF00164671","article-title":"Oxidative Reactions in the Tear Fluid of Patients Suffering from Dry Eyes","volume":"233","author":"Augustin","year":"1995","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1167\/iovs.06-1027","article-title":"Involvement of Oxidative Stress on Corneal Epithelial Alterations in a Blink-Suppressed Dry Eye","volume":"48","author":"Nakamura","year":"2007","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1167\/iovs.12-10325","article-title":"Evaluation of Lipid Oxidative Stress Status in Sj\u00f6gren Syndrome Patients","volume":"54","author":"Wakamatsu","year":"2013","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"7699","DOI":"10.4049\/jimmunol.1001099","article-title":"Tripartite-Motif Protein 30 Negatively Regulates NLRP3 Inflammasome Activation by Modulating Reactive Oxygen Species Production","volume":"185","author":"Hu","year":"2010","journal-title":"J. Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1167\/iovs.18-23965","article-title":"Hyperosmotic Stress\u2013Induced TRPM2 Channel Activation Stimulates NLRP3 Inflammasome Activity in Primary Human Corneal Epithelial Cells","volume":"59","author":"Zheng","year":"2018","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jtos.2020.07.001","article-title":"NLRP12- and NLRC4-Mediated Corneal Epithelial Pyroptosis Is Driven by GSDMD Cleavage Accompanied by IL-33 Processing in Dry Eye","volume":"18","author":"Chen","year":"2020","journal-title":"Ocul. Surf."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.2147\/JIR.S310116","article-title":"Calcitriol Alleviates Hyperosmotic Stress-Induced Corneal Epithelial Cell Damage via Inhibiting the NLRP3\u2013ASC\u2013Caspase-1\u2013GSDMD Pyroptosis Pathway in Dry Eye Disease","volume":"14","author":"Zhang","year":"2021","journal-title":"J. Inflamm. Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1167\/iovs.11-9417","article-title":"Correlations between Tear Cytokines, Chemokines, and Soluble Receptors and Clinical Severity of Dry Eye Disease","volume":"53","author":"Na","year":"2012","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/intimm\/dxn106","article-title":"The Phenotype of Human Th17 Cells and Their Precursors, the Cytokines That Mediate Their Differentiation and the Role of Th17 Cells in Inflammation","volume":"20","author":"Annunziato","year":"2008","journal-title":"Int. Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","article-title":"TFOS DEWS II Management and Therapy Report","volume":"15","author":"Jones","year":"2017","journal-title":"Ocul. Surf."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/sj.bjp.0706736","article-title":"How Corticosteroids Control Inflammation: Quintiles Prize Lecture 2005","volume":"148","author":"Barnes","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.exer.2006.02.004","article-title":"Corticosteroid and Doxycycline Suppress MMP-9 and Inflammatory Cytokine Expression, MAPK Activation in the Corneal Epithelium in Experimental Dry Eye","volume":"83","author":"Corrales","year":"2006","journal-title":"Exp. Eye Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1006\/pupt.2001.0283","article-title":"Glucocorticoid-Regulated Transcription Factors","volume":"14","author":"Adcock","year":"2001","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1677\/jme.0.0280069","article-title":"Negative Regulation of Nuclear Factor-\u039aB Activation and Function by Glucocorticoids","volume":"28","author":"Almawi","year":"2002","journal-title":"J. Mol. Endocrinol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0002-9394(03)00326-X","article-title":"The Comparison of Efficacies of Topical Corticosteroids and Nonsteroidal Anti-Inflammatory Drops on Dry Eye Patients: A Clinical and Immunocytochemical Study","volume":"136","author":"Avunduk","year":"2003","journal-title":"Am. J. Ophthalmol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0161-6420(99)90171-9","article-title":"Topical Nonpreserved Methylprednisolone Therapy for Keratoconjunctivitis Sicca in Sjogren Syndrome","volume":"106","author":"Marsh","year":"1999","journal-title":"Ophthalmology"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ajo.2003.10.036","article-title":"Antiinflammatory Therapy for Dry Eye","volume":"137","author":"Pflugfelder","year":"2004","journal-title":"Am. J. Ophthalmol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4068\/cmj.2015.51.1.26","article-title":"Long-Term Outcome of Treatment with Topical Corticosteroids for Severe Dry Eye Associated with Sj\u00f6gren\u2019s Syndrome","volume":"51","author":"Jung","year":"2015","journal-title":"Chonnam Med. J."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ophtha.2015.09.029","article-title":"Topical Fluorometholone Protects the Ocular Surface of Dry Eye Patients from Desiccating Stress: A Randomized Controlled Clinical Trial","volume":"123","author":"Fernandez","year":"2016","journal-title":"Ophthalmology"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"112351","DOI":"10.1016\/j.colsurfb.2022.112351","article-title":"A Topical Fluorometholone Nanoformulation Fabricated under Aqueous Condition for the Treatment of Dry Eye","volume":"212","author":"Wang","year":"2022","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Kala Pharmaceuticals Inc (2022, September 19). Eysuvis Full Prescribing Information, 1\u20139. Available online: https:\/\/www.eysuvis-ecp.com\/pdf\/prescribing-information.pdf.","DOI":"10.22233\/20412495.0922.1"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/ICO.0000000000002452","article-title":"Safety of KPI-121 Ophthalmic Suspension 0.25% in Patients With Dry Eye Disease: A Pooled Analysis of 4 Multicenter, Randomized, Vehicle-Controlled Studies","volume":"40","author":"Korenfeld","year":"2021","journal-title":"Cornea"},{"key":"ref_108","first-page":"259","article-title":"The Role of KPI-121 0.25% in the Treatment of Dry Eye Disease: Penetrating the Mucus Barrier to Treat Periodic Flares","volume":"9","author":"Gupta","year":"2018","journal-title":"Ther. Adv. Vaccines"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1210\/er.2005-0002","article-title":"The Search for Safer Glucocorticoid Receptor Ligands","volume":"26","author":"Rosen","year":"2005","journal-title":"Endocr. Rev."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/sj.eye.6701537","article-title":"Effects of the Topical Treatment with NSAIDs on Corneal Senstivity and Ocular Surface and Sj\u00f6gren\u2019s Syndrome Patients","volume":"19","author":"Aragona","year":"2005","journal-title":"Eye"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1089\/jop.2006.22.150","article-title":"Ketorolac During the Induction Phase of Cyclosporin-A Therapy","volume":"22","author":"Schechter","year":"2006","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1097\/ICO.0b013e31824988e5","article-title":"The Effect of Topical Pranoprofen 0.1% on the Clinical Evaluation and Conjunctival HLA-DR Expression in Dry Eyes","volume":"31","author":"Liu","year":"2012","journal-title":"Cornea"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00003226-200003000-00005","article-title":"Diclofenac Sodium, 0.1% (Voltaren Ophtha), versus Sodium Chloride, 5%, in the Treatment of Filamentary Keratitis","volume":"19","author":"Avisar","year":"2000","journal-title":"Cornea"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1167\/iovs.13-13850","article-title":"Diclofenac Protects Cultured Human Corneal Epithelial Cells against Hyperosmolarity and Ameliorates Corneal Surface Damage in a Rat Model of Dry Eye","volume":"55","author":"Sawazaki","year":"2014","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_115","unstructured":"McKinney, J. (2023, March 20). FDA Approves First Generic of Restasis, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-generic-restasis#:~:."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0162-3109(00)00192-2","article-title":"Mechanisms of Action of Cyclosporine","volume":"47","author":"Matsuda","year":"2000","journal-title":"Immunopharmacology"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1001\/archopht.1989.01070020276038","article-title":"Spontaneous Canine Keratoconjunctivitis Sicca. A Useful Model for Human Keratoconjunctivitis Sicca: Treatment with Cyclosporine Eye Drops","volume":"107","author":"Kaswan","year":"1989","journal-title":"Arch. Ophthalmol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1097\/ICO.0b013e31823cc098","article-title":"A Randomized Double-Masked Study of 0.05% Cyclosporine Ophthalmic Emulsion in the Treatment of Meibomian Gland Dysfunction","volume":"31","author":"Prabhasawat","year":"2012","journal-title":"Cornea"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1089\/jop.2006.22.47","article-title":"Efficacy of Topical Cyclosporin 0.05% in the Treatment of Posterior Blepharitis","volume":"22","author":"Rubin","year":"2006","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","article-title":"Two Multicenter Randomized Studies of the Efficacy and Safety of Cyclosporine Ophthalmic Emulsion in Moderate to Severe Dry Eye Disease","volume":"107","author":"Sall","year":"2000","journal-title":"Ophthalmology"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0161-6420(00)00035-X","article-title":"Efficacy and Safety of Cyclosporin A Ophthalmic Emulsion in the Treatment of Moderate-to-Servere Dry Eye Disease: A Dose-Ranging, Randomized Trial","volume":"107","author":"Stevenson","year":"2000","journal-title":"Ophthalmology"},{"key":"ref_122","first-page":"90","article-title":"Flow Cytometric Analysis of Inflammatory Markers in KCS: 6-Month Treatment with Topical Cyclosporin, A","volume":"42","author":"Brignole","year":"2001","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/00003226-200007000-00018","article-title":"Interleukin-6 Levels in the Conjunctival Epithelium of Patients with Dry Eye Disease Treated with Cyclosporine Ophthalmic Emulsion","volume":"19","author":"Turner","year":"2000","journal-title":"Cornea"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1167\/tvst.7.5.24","article-title":"Once-Daily Cyclosporine-A-MiDROPS for Treatment of Dry Eye Disease","volume":"7","author":"Coursey","year":"2018","journal-title":"Transl. Vis. Sci. Technol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"882803","DOI":"10.3389\/fphar.2022.882803","article-title":"Comparison of Seven Cyclosporine A Formulations for Dry Eye Disease: A Systematic Review and Network Meta-Analysis","volume":"13","author":"Gao","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.clae.2015.08.002","article-title":"On the Prescribing of Oral Doxycycline or Minocycline by UK Optometrists as Part of Management of Chronic Meibomian Gland Dysfunction (MGD)","volume":"39","author":"Doughty","year":"2016","journal-title":"Contact Lens Anterior Eye"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.ajo.2012.06.009","article-title":"Minocycline Controls Clinical Outcomes and Inflammatory Cytokines in Moderate and Severe Meibomian Gland Dysfunction","volume":"154","author":"Lee","year":"2012","journal-title":"Am. J. Ophthalmol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"125018","DOI":"10.1067\/mva.2002.125018","article-title":"Prolonged Administration of Doxycycline in Patients with Small Asymptomatic Abdominal Aortic Aneurysms: Report of a Prospective (Phase II) Multicenter Study","volume":"36","author":"Baxter","year":"2002","journal-title":"J. Vasc. Surg."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"5623","DOI":"10.1167\/iovs.09-4992","article-title":"Suppressive Effects of Azithromycin on Zymosan-Induced Production of Proinflammatory Mediators by Human Corneal Epithelial Cells","volume":"51","author":"Li","year":"2010","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1590\/S0004-27492012000300006","article-title":"Azithromycin 1.5% Ophthalmic Solution: Efficacy and Treatment Modalities in Chronic Blepharitis","volume":"75","author":"Fadlallah","year":"2012","journal-title":"Arq. Bras. Oftalmol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/ICO.0b013e3181ca38a0","article-title":"Multicenter Open-Label Study Evaluating the Efficacy of Azithromycin Ophthalmic Solution 1% on the Signs and Symptoms of Subjects with Blepharitis","volume":"29","author":"Haque","year":"2010","journal-title":"Cornea"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/bjophthalmol-2014-305410","article-title":"Oral Azithromycin versus Doxycycline in Meibomian Gland Dysfunction: A Randomised Double-Masked Open-Label Clinical Trial","volume":"99","author":"Kashkouli","year":"2015","journal-title":"Br. J. Ophthalmol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/106002809402800414","article-title":"Tacrolimus, a New Immunosuppressant\u2014A Review of the Literature","volume":"28","author":"Hooks","year":"1994","journal-title":"Ann. Pharmacother."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/341755a0","article-title":"A Cytosolic Binding Protein for the Immunosuppressant FKS06 Has Peptidyl-Prolyl Isomerase Activity but Is Distinct from Cyclophilin","volume":"342","author":"Siekierka","year":"1989","journal-title":"Nature"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.clae.2015.04.004","article-title":"Treatment of Sj\u00f6gren\u2019s Syndrome Dry Eye Using 0.03% Tacrolimus Eye Drop: Prospective Double-Blind Randomized Study","volume":"38","author":"Moscovici","year":"2015","journal-title":"Contact Lens Anterior Eye"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0753-3322(02)00253-6","article-title":"The Importance of the Ratio of Omega-6\/Omega-3 Essential Fatty Acids","volume":"56","author":"Simopoulos","year":"2002","journal-title":"Biomed. Pharmacother."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S1542-0124(12)70214-8","article-title":"Essential Fatty Acids in the Treatment of Dry Eye","volume":"8","author":"Rosenberg","year":"2010","journal-title":"Ocul. Surf."},{"key":"ref_138","first-page":"169","article-title":"Effectiveness and Tolerability of Dietary Supplementation with a Combination of Omega-3 Polyunsaturated Fatty Acids and Antioxidants in the Treatment of Dry Eye Symptoms: Results of a Prospective Study","volume":"8","year":"2014","journal-title":"Clin. Ophthalmol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.ophtha.2013.04.006","article-title":"Short-Term Consumption of Oral Omega-3 and Dry Eye Syndrome","volume":"120","author":"Kangari","year":"2013","journal-title":"Ophthalmology"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1755-3768.2011.02196.x","article-title":"A Multicentre, Double-Masked, Randomized, Controlled Trial Assessing the Effect of Oral Supplementation of Omega-3 and Omega-6 Fatty Acids on a Conjunctival Inflammatory Marker in Dry Eye Patients","volume":"89","author":"Baudouin","year":"2011","journal-title":"Acta Ophthalmol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jtos.2019.08.002","article-title":"The Dry Eye Assessment and Management (DREAM) Extension Study\u2014A Randomized Clinical Trial of Withdrawal of Supplementation with Omega-3 Fatty Acid in Patients with Dry Eye Disease","volume":"18","author":"Hussain","year":"2020","journal-title":"Ocul. Surf."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/ICL.0000000000000687","article-title":"Associations Between Systemic Omega-3 Fatty Acid Levels With Moderate-to-Severe Dry Eye Disease Signs and Symptoms at Baseline in the Dry Eye Assessment and Management Study","volume":"47","author":"Kuklinski","year":"2021","journal-title":"Eye Contact Lens"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa1709691","article-title":"N\u22123 Fatty Acid Supplementation for the Treatment of Dry Eye Disease","volume":"378","author":"Asbell","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_144","first-page":"CD011016","article-title":"Omega-3 and Omega-6 Polyunsaturated Fatty Acids for Dry Eye Disease","volume":"2019","author":"Downie","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"49","DOI":"10.18433\/jpps29895","article-title":"Lifitegrast Ophthalmic Solution 5.0% for Treatment of Dry Eye Disease: Overview of Clinical Trial Program","volume":"22","author":"Chan","year":"2019","journal-title":"J. Pharm. Pharm. Sci."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ophtha.2013.09.015","article-title":"Lifitegrast Ophthalmic Solution 5.0% for Treatment of Dry Eye Disease: Results of the OPUS-1 Phase 3 Study","volume":"121","author":"Sheppard","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.ophtha.2015.08.001","article-title":"Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease Results of the Randomized Phase III OPUS-2 Study","volume":"122","author":"Tauber","year":"2015","journal-title":"Ophthalmology"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ophtha.2016.09.025","article-title":"Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3)","volume":"124","author":"Holland","year":"2017","journal-title":"Ophthalmology"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/ICO.0000000000000803","article-title":"Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients with Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study","volume":"35","author":"Donnenfeld","year":"2016","journal-title":"Cornea"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus Kinases in Immune Cell Signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol. Rev."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.ophtha.2012.03.017","article-title":"Immunomodulatory Effect of the Topical Ophthalmic Janus Kinase Inhibitor Tofacitinib (CP-690,550) in Patients with Dry Eye Disease","volume":"119","author":"Huang","year":"2012","journal-title":"Ophthalmology"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.ophtha.2012.01.028","article-title":"Tofacitinib (CP-690,550), a Janus Kinase Inhibitor for Dry Eye Disease: Results from a Phase 1\/2 Trial","volume":"119","author":"Liew","year":"2012","journal-title":"Ophthalmology"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1097\/ICO.0b013e31817f3a0e","article-title":"Autologous Serum Eye Drops for the Treatment of Dry Eye Diseases","volume":"27","author":"Kojima","year":"2008","journal-title":"Cornea"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/bjo.85.10.1188","article-title":"Autologous Serum Eyedrops for Dry Eyes and Epithelial Defects: Clinical and in Vitro Toxicity Studies","volume":"85","author":"Poon","year":"2001","journal-title":"Br. J. Ophthalmol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/02713683.2013.824987","article-title":"The Application of Autologous Serum Eye Drops in Severe Dry Eye Patients; Subjective and Objective Parameters before and after Treatment","volume":"39","author":"Jirsova","year":"2014","journal-title":"Curr. Eye Res."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"684","DOI":"10.3109\/02713683.2012.674609","article-title":"Randomized Double-Blind Clinical Trial of Autologous Serum versus Artificial Tears in Dry Eye Syndrome","volume":"37","author":"Urzua","year":"2012","journal-title":"Curr. Eye Res."},{"key":"ref_157","first-page":"CD009327","article-title":"Autologous Serum Eye Drops for Dry Eye","volume":"2","author":"Pan","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Hong, S.C., Ha, J.H., Lee, J.K., Jung, S.H., and Kim, J.C. (2020). In Vivo Anti-Inflammation Potential of Aster Koraiensis Extract for Dry Eye Syndrome by the Protection of Ocular Surface. Nutrients, 12.","DOI":"10.3390\/nu12113245"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"101093","DOI":"10.1016\/j.redox.2018.101093","article-title":"Calcitriol Inhibits ROS-NLRP3-IL-1\u03b2 Signaling Axis via Activation of Nrf2-Antioxidant Signaling in Hyperosmotic Stress Stimulated Human Corneal Epithelial Cells","volume":"21","author":"Dai","year":"2019","journal-title":"Redox Biol."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Park, B., Jo, K., Lee, T.G., Hyun, S.W., Kim, J.S., and Kim, C.S. (2019). Polydatin Inhibits NLRP3 Inflammasome in Dry Eye Disease by Attenuating Oxidative Stress and Inhibiting the Nf-\u039ab Pathway. Nutrients, 11.","DOI":"10.3390\/nu11112792"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"14521","DOI":"10.1038\/s41598-020-71337-8","article-title":"HADSCs Derived Extracellular Vesicles Inhibit NLRP3inflammasome Activation and Dry Eye","volume":"10","author":"Yu","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41401-020-0484-5","article-title":"The Artemisinin Analog SM934 Alleviates Dry Eye Disease in Rodent Models by Regulating TLR4\/NF-\u039aB\/NLRP3 Signaling","volume":"42","author":"Yang","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/s41598-020-80849-2","article-title":"A Combination of CMC and \u03b1-MSH Inhibited ROS Activated NLRP3 Inflammasome in Hyperosmolarity Stressed HCECs and Scopolamine-Induced Dry Eye Rats","volume":"11","author":"Lv","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.dcmed.2021.03.006","article-title":"Linarin Ameliorates Innate Inflammatory Response in an Experimental Dry Eye Model via Modulation of the NLRP3 Inflammasome","volume":"4","author":"Chen","year":"2021","journal-title":"Digit. Chin. Med."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000519458","article-title":"Exosomes Derived from Mouse Adipose-Derived Mesenchymal Stem Cells Alleviate Benzalkonium Chloride-Induced Mouse Dry Eye Model via Inhibiting NLRP3 Inflammasome","volume":"65","author":"Wang","year":"2022","journal-title":"Ophthalmic Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/13\/10866\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:03:46Z","timestamp":1760126626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/13\/10866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,29]]},"references-count":165,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["ijms241310866"],"URL":"https:\/\/doi.org\/10.3390\/ijms241310866","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,29]]}}}